on PolyPeptide Group
PolyPeptide Group Reports Solid Progress and Upgrades FY 2024 Guidance
PolyPeptide Group AG has announced significant progress in the first half (H1) of 2024, with revenue reaching EUR 135.0 million, marking a 2.4% increase compared to H1 2023. The company's EBITDA climbed to EUR 2.9 million from a negative EUR 19.4 million, driven by better operational efficiency and a favorable product mix.
The company is advancing capacity expansion projects across Belgium, Sweden, France, and the United States, with capital expenditures hitting EUR 20.5 million in H1 2024. The guidance for the full year 2024 has been upgraded, now expecting high single-digit revenue growth and a positive mid-single-digit EBITDA margin.
PolyPeptide's mid-term target aims to double its 2023 revenue by 2028, with plans supported by current customer commitments. EBITDA margins are projected to approach 25% by 2028. The company continues to focus on capacity expansion and commercial excellence.
An audio webcast and conference call discussing these results will take place today at 9:30 am CEST.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PolyPeptide Group news